“…However, the results remained unsatisfactory due in part to the molecular selectivity of the blood-brain barrier (BBB), which prevented the crossing of most drugs investigated for the treatment of this disease, or because they only targeted one aspect of the disease. In this context, the pituitary adenylate cyclase-activating polypeptide (PACAP) is a promising molecule for the development of a therapeutic strategy to cure a neurodegenerative disease such as PD, because it crosses the BBB and exhibits anti-apoptotic, anti-inflammatory and anti-oxidant activities (Nishimoto et al, 2007;Ravni et al, 2006;Reglodi et al, 2004a;Shioda et al, 2006). Indeed, PACAP has been shown to exert neuroprotective effects in experimental models of neurodegeneration, cerebral ischemia and brain injuries (Deguil et al, 2007;Lazarovici et al, 2012;Lee and Seo, 2014;Rat et al, 2011;Reglodi et al, 2011;Tamas et al, 2012).…”